Mr. Norden is a senior executive with more than 25 years of leadership in financial management and strategy, including a 21-year career at Wyeth, where he was most recently Senior Vice President and Chief Financial Officer. Wyeth was acquired by Pfizer in October 2009 in a transaction valued at $68 billion. Prior to his corporate CFO role, Mr. Norden was Executive Vice President and Chief Financial Officer, Wyeth Pharmaceuticals and held a number of other positions of increasing responsibility from initially joining Wyeth/American Home Products in 1989. Earlier in his career, Mr. Norden worked at Arthur Andersen & Co.
"With a rapidly growing life sciences business and a capability for developing high-value molecular diagnostics, NanoString Technologies is poised to transform both the study and treatment of disease," said Mr. Norden. "I am excited to join NanoString's Board of Directors, and to help the company scale these businesses."
Mr. Norden received his B.S. from the State University of New York - Plattsburgh and received his M.S. from Long Island University - C. W. Post. He also serves on the Board of Directors of Human Genome Sciences /quotes/zigman/55662/quotes/nls/hgsi HGSI +0.04% , a public biopharmaceutical company, and WelchAllyn, a leading global provider of medical diagnostic equipment.
"Greg brings more than two decades of healthcare industry experience and an impeccable track record of leading financial and administrative operations," said William D. Young, Executive Chairman of the Board for NanoString Technologies. "We look forward to benefiting from his experience as CFO of a global Fortune 120 corporation as we prepare for the next stage of NanoString's growth."